Network analysis of FDA approved drugs and their targets
Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · 2007
DOI: 10.1002/msj.20002 ↗At a glance
Journal article in Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2007. Written by Avi Ma'ayan and 3 co-authors. Institution: Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York 10029, USA. Major MEDLINE topics: Computational Biology, Databases, Factual, Drug Approval, United States Food and Drug Administration. Cited 96 times so far (Crossref); 13 references. The full text is freely available in PubMed Central. Funded by: NIGMS NIH HHS.
Abstract (original language)
The global relationship between drugs that are approved for therapeutic use and the human genome is not known. We employed graph‐theory methods to analyze the Federal Food and Drug Administration (FDA) approved drugs and their known molecular targets. We used the FDA Approved Drug Products with Therapeutic Equivalence Evaluations 26 th Edition Electronic Orange Book (EOB) to identify all FDA approved drugs and their active ingredients. We then connected the list of active ingredients extracted from the EOB to those known human protein targets included in the DrugBank database and constructed a bipartite network. We computed network statistics and conducted Gene Ontology analysis on the drug targets and drug categories. We find that drug to drug‐target relationship in the bipartite network is scale‐free. Several classes of proteins in the human genome appear to be better targets for drugs since they appear to be selectively enriched as drug targets for the currently FDA approved drugs. These initial observations allow for development of an integrated research methodology to identify general principles of the drug discovery process. Mt Sinai J Med 74:27–32, 2007. © 2007 Mount Sinai School of Medicine
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York 10029, USA.
Funding
- NIGMS NIH HHS
Cite
APA
Ma'ayan, A., Jenkins, S. L., Goldfarb, J., & Iyengar, R. (2007). Network analysis of FDA approved drugs and their targets. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine. https://doi.org/10.1002/msj.20002
Vancouver
Ma'ayan A, Jenkins SL, Goldfarb J, Iyengar R. Network analysis of FDA approved drugs and their targets. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine. 2007. doi:10.1002/msj.20002
BibTeX
@article{Maayan2007,
author = {Ma'ayan, Avi and Jenkins, Sherry L and Goldfarb, Joseph and Iyengar, Ravi},
title = {Network analysis of FDA approved drugs and their targets},
journal = {Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine},
year = {2007},
doi = {10.1002/msj.20002}
}
EUVIMED